Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Study of Irinotecan Plus 5-fluorouracil Plus Leucovorin and Bevacizumab (FOLFIRI+Avastin) Versus Irinotecan Plus Capecitabine and Bevacizumab (XELIRI+Avastin) as 1st Line Treatment of Locally Advanced or Metastatic Colorectal Cancer
Brief Summary: This phase III study will compare two combinations of irinotecan, Folfiri versus Xeliri, with the addition of Avastin as 1st line treatment of colorectal cancer.


Options:
A: Arm Label: FOLFIRI +/- Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Drug: CPT-11 (Irinotecan), Drug: 5-FU Bolus, Drug: 5-FU Infusion, Drug: l-LV (dl-LV) | Arm Label: XELIRI +/- Bevacizumab; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: CPT-11 (Irinotecan), Drug: Capecitabine | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: CPT-11 (Irinotecan); Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: 5-FU Bolus; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: 5-FU Infusion; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: l-LV (dl-LV); Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): XELIRI +/- Bevacizumab | Intervention Type: DRUG; Name: CPT-11 (Irinotecan); Assigned to Arm(s): XELIRI +/- Bevacizumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): XELIRI +/- Bevacizumab
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Irinotecan, Drug: 5-Fluorouracil, Drug: Leucovorin, Drug: Bevacizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine, Drug: Bevacizumab, Drug: Irinotecan | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): 2
C: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy, Drug: Bevacizumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab
D: Arm Label: FOLFIRI + Ramucirumab; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab, Drug: Irinotecan, Drug: Folinic Acid, Drug: 5-Fluorouracil | Arm Label: FOLFIRI + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Irinotecan, Drug: Folinic Acid, Drug: 5-Fluorouracil | Intervention Type: BIOLOGICAL; Name: Ramucirumab; Assigned to Arm(s): FOLFIRI + Ramucirumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): FOLFIRI + Placebo | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab | Intervention Type: DRUG; Name: Folinic Acid; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab

Answer: B